Literature DB >> 6978782

Spontaneous mouse erythrocyte-rosette formation in chronic lymphocytic leukaemia.

E Kuhlein, G Laurent, F Rigal, G Delsol, J Pris, J Ducos.   

Abstract

Mouse erythrocyte-rosette-forming cells (MRFC) were determined in 76 cases of chronic lymphocytic leukaemia (CLL), 19 cases of centroblastic-centrocytic follicular non-Hodgkin's lymphoma (NHL), five cases of hairy cell leukaemia (HCL) and in 62 control patients. The mean percentage of MRFC in B-CLL was 54.8% +/- 24.4%, in nodular centro-follicular NHL 2.3% +/- 3%, in hairy cell leukaemia 14.6% +/-14.7% and among the controls 3.2% +/- 1.9%. Thus, MRFC appear to be an excellent marker of B-CLL and sometimes the only B cell marker as in 11 cases of SIg negative CLL. There is no correlation between the percentage of MRFC and clinical staging according to Rai classification whereas patients with stage 2 in Binet's classification (isolated splenomegaly) have a significantly lower MRFC percentage (23.4% +/- 27.7%; P less than 0.05). There is no correlation with prognosis, nor with serum Ig levels. We found no correlation with surface phenotype IgM, IgM-IgD or IgG. Thus, this study does not confirm the hypothesis that MRFC might characterize and immature stage in the B lymphocyte differentiation. However, these results are consistent with another hypothesis which states that lymphocytes in CLL possibly originate from a clonal expansion of a normal B lymphocyte subset, characterized by a low concentration of SIg and a receptor for mouse erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978782      PMCID: PMC1536522     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Rosette-formation with mouse erythrocytes. II. A marker for human B and non-T lymphocytes.

Authors:  S Gupta; R A Good; F P Siegal
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

2.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

3.  Non-immunoglobulin-bearing 'B' lymphocytes in chronic lymphatic leukaemia?

Authors:  H McLaughlin; G Wetherly-Mein; C Pitcher; J R Hobbs
Journal:  Br J Haematol       Date:  1973-07       Impact factor: 6.998

4.  Formation of mouse or sheep red-blood-cell rosettes by lymphocytes from normal and leukaemic individuals.

Authors:  G Stathopoulos; E V Elliott
Journal:  Lancet       Date:  1974-04-06       Impact factor: 79.321

5.  Surface immunoglobulins in chronic lymphatic leukaemia, macroglobulinaemia and myelomatosis.

Authors:  W Knapp; H R Schuit; R L Bolhuis; W Hijmans
Journal:  Clin Exp Immunol       Date:  1974-04       Impact factor: 4.330

6.  Receptor sites for complement on certain human peripheral blood lymphocytes.

Authors:  G Michlmayr; H Huber
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

7.  Mouse red-cell rosettes in B-lymphoproliferative disorders.

Authors:  D Catovsky; M Cherchi; A Okos; U Hegde; D A Galton
Journal:  Br J Haematol       Date:  1976-06       Impact factor: 6.998

8.  Rosette formation with mouse erythrocytes: probable marker for human B lymphocytes.

Authors:  S Gupta; M H Grieco
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

9.  Ontogeny of lymphocyte subpopulations in human fetal liver.

Authors:  S Gupta; R Pahwa; R O'Reilly; R A Good; F P Siegal
Journal:  Proc Natl Acad Sci U S A       Date:  1976-03       Impact factor: 11.205

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  1 in total

1.  Crossreaction of monoclonal anti-T-cell antibodies: implications for classifying B-cell leukemias.

Authors:  R Munker; E Thiel; U Kummer; H Rodt; S Thierfelder
Journal:  Blut       Date:  1983-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.